4-(6-methoxy-1,3-benzothiazol-2-y)benzonitrie | 17930-13-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 4-(6-methoxy-1,3-benzothiazol-2-y)benzonitrie
• 英文别名: 2-(p-Cyan-phenyl)-6-methoxy-benzthiazol；4-(6-methoxybenzo[d]thiazol-2-yl)benzonitrile；4-(6-methoxy-benzothiazol-2-yl)-benzonitrile；4-(6-methoxy-1,3-benzothiazol-2-yl)benzonitrile
• CAS: 17930-13-1
• 化学式: C₁₅H₁₀N₂OS
• 分子量: 266.323
• InChiKey: ZIKYQHVPEWMFIU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  74.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-氰基苯硼酸 、 2-溴-6-甲氧基苯并噻唑 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 生成 4-(6-methoxy-1,3-benzothiazol-2-y)benzonitrie
  参考文献：
  名称：

  A Basis for Reduced Chemical Library Inhibition of Firefly Luciferase Obtained from Directed Evolution

  摘要：

  We measured the "druggability" of the ATP-dependent luciferase derived from the firefly Photuris pennsylvanica that was optimized using directed evolution (Ultra-Glo, Promega). Quantitative high-throughput screening (qHTS) was used to determine IC(50)S of 198899 samples against a formulation of Ultra-Glo luciferase (Kinase-Glo). We found that only 0.1 % of the Kinase-Glo inhibitors showed an IC(50) < 10 mu M compared to 0.9% found from a previous qHTS against the firefly luciferase from Photinus pyralis (lucPpy). Further, the maximum affinity identified in the lucPpy qHTS was 50 nM, while for Kinase-Glo this value increased to 600 nM. Compounds with interactions stretching outside the luciferin binding pocket were largely lost with Ultra-Glo luciferase. Therefore, Ultra-Glo luciferase will show less compound interference when used as an ATP sensor compared to lucPpy. This study demonstrates the power of large-scale quantitative analysis of structure-activity relationships (> 100K compounds) in addressing important questions such as a target's druggability.

  DOI：

  10.1021/jm8014525

文献信息

• [EN] PROBES FOR IMAGING HUNTINGTIN PROTEIN<br/>[FR] SONDES D'IMAGERIE DE LA PROTÉINE HUNTINGTINE
  申请人：CHDI FOUNDATION INC

  公开号：WO2016033460A1

  公开（公告）日：2016-03-03

  Provided are imaging agents comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use.

  提供的是包含式(I)化合物或其药学上可接受的盐的成像剂，以及它们的使用方法。
• Probes for imaging huntingtin protein
  申请人：CHDI Foundation, Inc.

  公开号：US10907197B2

  公开（公告）日：2021-02-02

  Provided are imaging agents comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use.

  本文提供了由式（I）化合物或其药学上可接受的盐组成的成像剂及其使用方法。
• Compounds for targeting mutant huntingtin protein and uses thereof
  申请人：CHDI Foundation, Inc.

  公开号：US11389438B2

  公开（公告）日：2022-07-19

  The present disclosure relates generally to compounds that simultaneously bind both mutant huntingtin protein (mHTT) and an ubiquitin E3 ligase and their use as therapeutic agents, for example, in treating diseases, such as neurodegenerative disorders caused by aggregation of mHTT.

  本公开总体上涉及同时结合突变亨廷汀蛋白（mHTT）和泛素 E3 连接酶的化合物及其作为治疗剂的用途，例如，用于治疗疾病，如由 mHTT 聚合引起的神经退行性疾病。
• PROBES FOR IMAGING HUNTINGTIN PROTEIN
  申请人：CHDI Foundation, Inc.

  公开号：EP3190888A1

  公开（公告）日：2017-07-19
• COMPOUNDS FOR TARGETING MUTANT HUNTINGTIN PROTEIN AND USES THEREOF
  申请人：CHDI Foundation, Inc.

  公开号：EP3931186A1

  公开（公告）日：2022-01-05